Navigation Links
Insights gained from growing cold-causing virus on sinus tissue
Date:4/10/2011

MADISON - Using sinus tissue removed during surgery at University of Wisconsin Hospital and Clinics, researchers at the University of Wisconsin-Madison have managed to grow a recently discovered species of human rhinovirus (HRV), the most frequent cause of the common cold, in culture.

The researchers found that the virus, which is associated with up to half of all HRV infections in children, has reproductive properties that differ from those of other members of the HRV family.

The accomplishments, reported in Nature Medicine on April 11, should allow antiviral compounds to be screened to see if they stop the virus from growing.

The report sheds light on HRV-C, a new member of the HRV family that also includes the well-known HRV-A and HRV-B. Discovered five years ago, HRV-C has been notoriously difficult to grow in standard cell cultures and, therefore, impossible to study.

"We now have evidence that there may be new approaches to treating or preventing HRV-C infections," says senior author James Gern, professor of medicine at the UW-Madison School of Medicine and Public Health and an asthma expert at American Family Children's Hospital.

Future drugs could be especially useful for children and adults who have asthma and other lung problems, Gern says.

Recent studies have shown that in addition to its major role in the common cold, HRV-C is responsible for between 50 percent and 80 percent of asthma attacks. HRV-C is a frequent cause of wheezing illnesses in infants and may be especially likely to cause asthma attacks in children. HRV infections of all kinds also can greatly worsen chronic lung diseases such as cystic fibrosis and chronic obstructive pulmonary disease.

Like other scientists, Yury Bochkov, a virologist in Gern's lab, was unable to grow HRV-C in standard cell lines. So he turned to nasal tissue he collected following sinus surgeryand was surprised to find success. He grew significant amounts of two forms of HRV-C, then sequenced the complete virus genome and engineered an identical copy of it in a plasmid vector.

Studying the reproduction of the living, growing virus, he found that HRV-C replication appeared to occur in specific kinds of cells localized in nasal epithelium tissue.

"We also found that HRV-C does not attach to the two receptors that HRV-A and HRV-B use," Bochkov says. "HRV-C uses a distinct, yet unknown, receptor that is absent or under-expressed in many cell lines."

HRV-C also responded differently to antibodies that block receptor binding.

"Antibodies that normally keep HRV-A and HRV-B from binding to their receptors did not prevent HRV-C from binding to them," Bochkov says.

The findings suggest that new approaches are needed to treat HRV-C, says Gern.

"Previous drug candidates for the common cold were tested only against HRV-A and HRV-B," he says. "For more effective medications, we need to also target HRV-C."

Bochkov will continue to use the organ culture system to study details of HRV-C biology.

"It's now clear that these viruses have unique growth requirements," he says.


'/>"/>

Contact: Toni Morrissey
tmorrissey@uwhealth.org
608-263-3223
University of Wisconsin-Madison
Source:Eurekalert

Related medicine news :

1. Bird embryo provides unique insights into development related to cancer and wound healing
2. New insights into cancer treatment
3. Scientists reveal new insights into tendon injury
4. First Look at Prostate Cancer Genome Yields Insights
5. New Insights on Who Should Take Erbitux for Colon Cancer
6. Sodium MRI gives new insights into detecting osteoarthritis, NYU researchers find
7. Snake venom studies yield insights for development of therapies for heart disease and cancer
8. Cell symposia meeting, Influenza: Translating basic insights, to be held Dec. 2-4, 2010
9. From head to toe: Deep insights from whole body MRI
10. Emerald Express International to be Featured on ‘Insights' with Hugh Downs this Spring in a Segment that Spotlights Glutathione and Anti-Aging
11. Expert Insights on Health Data Sharing, Collaboration, Quality and Meaningful Use Featured in Latest Carefx Position Paper
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/17/2017)... ... February 17, 2017 , ... Qualis Health, one of the ... 8th Annual DecisionHealth Platinum Awards in recognition of its innovative healthcare management programs ... across multiple award categories, highlighting four of the organization’s current programs:, ...
(Date:2/17/2017)... , ... February 17, 2017 , ... ... operations executives and focusing on all facets of clinical trial planning and management. ... , patient engagement, and more. In addition, attendees stopping by Pharmica’s booth were ...
(Date:2/17/2017)... ... 2017 , ... Top neuroendocrine cancer doctors, nurses and specialists from around the ... - 23 in Beaver Creek, CO. It was announced today by Cindy Lovelace, executive ... Beaver Creek, hosting over 60 faculty members and addressing unmet needs of the NET ...
(Date:2/16/2017)... ... February 17, 2017 , ... ... last long after their final treatments. Physician researchers at The Marcus Institute ... a mind-body therapy, for efficacy in reducing symptoms of traumatic stress in cancer ...
(Date:2/16/2017)... ... February 16, 2017 , ... Doctors on Liens is proud ... their network through his work at BKP Chiropractic in Lancaster . ... degree from Canada’s prestigious International Baccalaureate Program, Dr. Raj went on to open ...
Breaking Medicine News(10 mins):
(Date:2/17/2017)... , February 17, 2017 Cryoablation, Electrical, ... The global ablation technologies market is expected to grow ... from 2022-2027. The market is expected to grow at a CAGR ... $3.3bn in 2016, and $9.05bn in 2026. ... How this report will benefit you ...
(Date:2/17/2017)... , February 17, 2017 According to ... Particle Counters, Liquid Particle Counters), Application (Cleanroom Monitoring, Contamination Monitoring of ... to 2021" published by MarketsandMarkets, the market is expected to reach ... at a CAGR of 3.7% from 2016 to 2021. ... ...
(Date:2/17/2017)... 17, 2017 Theravance Biopharma, Inc. (NASDAQ: ... "Company") today announced the presentation of positive clinical ... administered pan-Janus kinase (JAK) inhibitor designed to be ... of the European Crohn,s and Colitis Organization (ECCO). ... data from its completed Phase 1 study of ...
Breaking Medicine Technology: